Takeda Teijin Unit Get U.S. Approval For Gout Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals and its Teijin Pharma U.S. subsidiary said the U.S. FDA has cleared their Uloric (febuxostat) for treating gout. The drug is unique in that it is available to patients with kidney or liver ailments. The drug works by inhibiting an enzyme that produces ulric acid that leads to gout. The two firms plan to introduce Uloric in March to the U.S. market and its 5 million gout patients. (Click here for more - a subscription may be required